Press Release

Genesis Therapeutics Closes Oversubscribed $200 Million Series B

August 21, 2023

Palo Alto – August 21, 2023 – Cooley advised Andreessen Horowitz (a16z) Bio + Health Tech Investments, an a16z fund with a focus on biotechnology and healthcare technology, in connection with Genesis Therapeutics’ oversubscribed $200 million Series B financing. Lawyers Josh Seidenfeld and Thomas Heiser led the Cooley team advising a16z Bio + Health.

Genesis will use proceeds from the round to advance its existing, wholly owned pipeline of artificial intelligence-enabled programs into clinical development, invest in continued development of novel and state-of-the-art generative and predictive AI methods, and expand its pipeline.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.